Human urinary GM2-activator protein as a potential biomarker for lung cancer

Human urine can be obtained from most patients by noninvasive ways of collection. It is a rich source of biomarkers for diagnostic tests, therapeutic guidance and prognostic information for patients and clinicians. Recently, the protein expression pattern of urine samples from lung cancer patients a...

Full description

Saved in:
Bibliographic Details
Main Authors: Potprommanee L., Ma H.-T., Chen C.-H., Aobchey P., Boonyapranai K., Chewaskulyong B., Sangthong P., Shank L., Chen S.-T.
Format: Article
Language:English
Published: 2014
Online Access:http://www.scopus.com/inward/record.url?eid=2-s2.0-84889657116&partnerID=40&md5=9e18161deb2b115f6ce7c0249a69bc8b
http://cmuir.cmu.ac.th/handle/6653943832/7392
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English
id th-cmuir.6653943832-7392
record_format dspace
spelling th-cmuir.6653943832-73922014-08-30T04:00:56Z Human urinary GM2-activator protein as a potential biomarker for lung cancer Potprommanee L. Ma H.-T. Chen C.-H. Aobchey P. Boonyapranai K. Chewaskulyong B. Sangthong P. Shank L. Chen S.-T. Human urine can be obtained from most patients by noninvasive ways of collection. It is a rich source of biomarkers for diagnostic tests, therapeutic guidance and prognostic information for patients and clinicians. Recently, the protein expression pattern of urine samples from lung cancer patients and healthy controls were compared using two-dimensional gel electrophoresis (2-DE). GM2 activator protein (GM2AP) in lung cancer patients with 2.5-4.0 folds higher than that found in healthy controls was the protein of interest, and this protein was focused because it is related to tumor-associated gangliosides found in cancer progression. The aim of this study was to investigate the urinary biomarkers associated with lung cancer. First, we applied proteomic approach to confirm the increase level of GM2AP in urine samples from lung cancer patients and healthy controls. Then, the expression level of urinary GM2AP was quantified using Western blotting and Enzyme-Linked Immunosorbent Assay (ELISA). The results show that the expression level of GM2AP significantly increased in each subtype of lung cancer patients (P<0.05). In addition, nano liquid chromatography coupled online with tandem mass spectrometry (NanoLC-MS/ MS) provided evidence of an increase of GM2AP with the glycan structure identification from doublely charge at m/z 1202.1025 corresponding to the structure of (Hex)3(HexNAc)2(Fuc)1 linked with peptide (PIIVOGNVTLSVVG). Overall data suggested that the GM2AP may be associated with lung cancer and may be useful as a marker to monitor lung cancer prognosis. © 2013 Potprommanee L, et al. 2014-08-30T04:00:56Z 2014-08-30T04:00:56Z 2013 Article 0974276X 10.4172/jpb.1000289 http://www.scopus.com/inward/record.url?eid=2-s2.0-84889657116&partnerID=40&md5=9e18161deb2b115f6ce7c0249a69bc8b http://cmuir.cmu.ac.th/handle/6653943832/7392 English
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
language English
description Human urine can be obtained from most patients by noninvasive ways of collection. It is a rich source of biomarkers for diagnostic tests, therapeutic guidance and prognostic information for patients and clinicians. Recently, the protein expression pattern of urine samples from lung cancer patients and healthy controls were compared using two-dimensional gel electrophoresis (2-DE). GM2 activator protein (GM2AP) in lung cancer patients with 2.5-4.0 folds higher than that found in healthy controls was the protein of interest, and this protein was focused because it is related to tumor-associated gangliosides found in cancer progression. The aim of this study was to investigate the urinary biomarkers associated with lung cancer. First, we applied proteomic approach to confirm the increase level of GM2AP in urine samples from lung cancer patients and healthy controls. Then, the expression level of urinary GM2AP was quantified using Western blotting and Enzyme-Linked Immunosorbent Assay (ELISA). The results show that the expression level of GM2AP significantly increased in each subtype of lung cancer patients (P<0.05). In addition, nano liquid chromatography coupled online with tandem mass spectrometry (NanoLC-MS/ MS) provided evidence of an increase of GM2AP with the glycan structure identification from doublely charge at m/z 1202.1025 corresponding to the structure of (Hex)3(HexNAc)2(Fuc)1 linked with peptide (PIIVOGNVTLSVVG). Overall data suggested that the GM2AP may be associated with lung cancer and may be useful as a marker to monitor lung cancer prognosis. © 2013 Potprommanee L, et al.
format Article
author Potprommanee L.
Ma H.-T.
Chen C.-H.
Aobchey P.
Boonyapranai K.
Chewaskulyong B.
Sangthong P.
Shank L.
Chen S.-T.
spellingShingle Potprommanee L.
Ma H.-T.
Chen C.-H.
Aobchey P.
Boonyapranai K.
Chewaskulyong B.
Sangthong P.
Shank L.
Chen S.-T.
Human urinary GM2-activator protein as a potential biomarker for lung cancer
author_facet Potprommanee L.
Ma H.-T.
Chen C.-H.
Aobchey P.
Boonyapranai K.
Chewaskulyong B.
Sangthong P.
Shank L.
Chen S.-T.
author_sort Potprommanee L.
title Human urinary GM2-activator protein as a potential biomarker for lung cancer
title_short Human urinary GM2-activator protein as a potential biomarker for lung cancer
title_full Human urinary GM2-activator protein as a potential biomarker for lung cancer
title_fullStr Human urinary GM2-activator protein as a potential biomarker for lung cancer
title_full_unstemmed Human urinary GM2-activator protein as a potential biomarker for lung cancer
title_sort human urinary gm2-activator protein as a potential biomarker for lung cancer
publishDate 2014
url http://www.scopus.com/inward/record.url?eid=2-s2.0-84889657116&partnerID=40&md5=9e18161deb2b115f6ce7c0249a69bc8b
http://cmuir.cmu.ac.th/handle/6653943832/7392
_version_ 1681420791350034432